Our previous study demonstrated that H2Mab-19 significantly reduced tumor development in HER2-expressing breast cancer cells (BT-474), oral cancer cells (HSC-2 and SAS) and CRC cells (Caco-2) xenograft models, suggesting that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing cancers (27,28). This evidence concerns the gene ERBB2 and colorectal carcinoma.